步长制药
(603858)
| 流通市值：181.60亿 | | | 总市值：181.60亿 |
| 流通股本：10.55亿 | | | 总股本：10.55亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,468,581,319.22 | 5,663,836,253.89 | 2,784,946,981.48 | 11,005,794,900.15 |
| 营业收入 | 8,468,581,319.22 | 5,663,836,253.89 | 2,784,946,981.48 | 11,005,794,900.15 |
| 二、营业总成本 | 7,531,602,618.43 | 4,990,838,810.29 | 2,463,700,632.04 | 10,388,210,007.49 |
| 营业成本 | 3,192,193,227.23 | 2,130,994,967.96 | 1,063,955,134.14 | 4,427,650,741.4 |
| 税金及附加 | 125,709,791.24 | 84,252,129.22 | 44,733,034.13 | 159,019,064.85 |
| 销售费用 | 3,341,254,788.63 | 2,239,340,547.33 | 1,090,082,446.58 | 4,323,174,318.36 |
| 管理费用 | 633,582,140.13 | 394,727,994.4 | 192,314,068.59 | 1,010,181,015.43 |
| 研发费用 | 153,627,979.11 | 84,196,636.41 | 45,145,869.88 | 345,408,287.11 |
| 财务费用 | 85,234,692.09 | 57,326,534.97 | 27,470,078.72 | 122,776,580.34 |
| 其中:利息费用 | 88,586,777.48 | 59,869,654.26 | 28,740,161.81 | 129,588,548.4 |
| 其中:利息收入 | 4,190,242.96 | 3,148,463.53 | 1,590,764.01 | 7,525,042.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 13,706,548.91 | 3,377,528.63 | 2,075,377.83 | -149,331.32 |
| 加:投资收益 | 5,342,536.48 | 4,570,467.9 | -608,269.39 | 13,020,046.98 |
| 资产处置收益 | 152,441.02 | 157,220.65 | 161,548.95 | 427,415.37 |
| 资产减值损失(新) | -8,355,874.39 | 2,601,071.04 | 2,314,194.22 | -977,512,390.37 |
| 信用减值损失(新) | 31,954,870.19 | 34,276,981.07 | 26,440,575.02 | 22,585,406.01 |
| 其他收益 | 69,322,635.29 | 49,767,597.12 | 31,185,034.75 | 77,289,783.6 |
| 四、营业利润 | 1,049,101,858.29 | 767,748,310.01 | 382,814,810.82 | -246,754,177.07 |
| 加:营业外收入 | 3,214,964.97 | 1,727,186.77 | 1,278,138.54 | 4,924,813.43 |
| 减:营业外支出 | 31,737,779.7 | 19,883,951.03 | 7,964,368.91 | 123,462,199.87 |
| 五、利润总额 | 1,020,579,043.56 | 749,591,545.75 | 376,128,580.45 | -365,291,563.51 |
| 减:所得税费用 | 229,450,624.66 | 159,362,361.9 | 86,238,376.36 | 337,103,089.74 |
| 六、净利润 | 791,128,418.9 | 590,229,183.85 | 289,890,204.09 | -702,394,653.25 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 791,128,418.9 | 590,229,183.85 | 289,890,204.09 | -702,394,653.25 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 868,323,718.42 | 627,701,257.33 | 307,261,088.17 | -553,797,938.8 |
| 少数股东损益 | -77,195,299.52 | -37,472,073.48 | -17,370,884.08 | -148,596,714.45 |
| 扣除非经常损益后的净利润 | 855,105,661.35 | 618,837,568.16 | 299,588,268.04 | -492,701,984.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.82 | 0.59 | 0.29 | -0.51 |
| (二)稀释每股收益 | 0.82 | 0.59 | 0.29 | -0.51 |
| 八、其他综合收益 | -50,998.71 | 312,653.69 | -935,561.51 | -605,746.2 |
| 归属于母公司股东的其他综合收益 | -50,998.71 | 312,653.69 | -935,561.51 | -605,746.2 |
| 九、综合收益总额 | 791,077,420.19 | 590,541,837.54 | 288,954,642.58 | -703,000,399.45 |
| 归属于母公司股东的综合收益总额 | 868,272,719.71 | 628,013,911.02 | 306,325,526.66 | -554,403,685 |
| 归属于少数股东的综合收益总额 | -77,195,299.52 | -37,472,073.48 | -17,370,884.08 | -148,596,714.45 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |